keyword
MENU ▼
Read by QxMD icon Read
search

Advanced lung cancer

keyword
https://www.readbyqxmd.com/read/28110461/the-emerging-role-of-liquid-biopsies-circulating-tumor-cells-and-circulating-cell-free-tumor-dna-in-lung-cancer-diagnosis-and-identification-of-resistance-mutations
#1
REVIEW
Angela Esposito, Carmen Criscitiello, Dario Trapani, Giuseppe Curigliano
Therapeutic advances in the treatment of lung cancer are in part due to a more complete understanding of its genomic portrait. The serial monitoring of tumor genotypes, which are instable and prone to changes under selective pressure, is becoming increasingly needed. Although tumor biopsies remain the reference standard for the diagnosis and genotyping of lung cancer, they are invasive and not always feasible. The "liquid biopsies" have the potential to overcome many of these hurdles, allowing a rapid and accurate identification of de novo and resistant genetic alterations and a real-time monitoring of treatment responses...
January 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28110254/leptomeningeal-carcinomatosis-in-non-small-cell-lung-cancer-patients-a-continuing-challenge-in-the-personalized-treatment-era
#2
REVIEW
J Remon, E Le Rhun, B Besse
Leptomeningeal metastasis is a fatal manifestation seen in advanced cancer patients. Its incidence is increasing, reaching 3.8% in molecularly unselected non-small cell lung cancer patients and up to 5% and 9% in ALK-rearranged and EGFR-mutant lung cancer patients, respectively. The prognosis remains poor despite systemic treatment, intrathecal chemotherapy, radiation therapy and personalized treatments in molecularly selected patients. However, new therapies with improved cerebral-spinal fluid penetration have been developed for subgroups of molecular selected patients indicating they could be promising therapeutic options for managing leptomeningeal disease...
December 30, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28109804/increasing-rates-of-no-treatment-in-advanced-stage-non-small-cell-lung-cancer-patients-a%C3%A2-propensity-matched-analysis
#3
Elizabeth A David, Megan E Daly, Chin-Shang Li, Chi-Lu Chiu, David T Cooke, Lisa M Brown, Joy Melnikow, Karen Kelly, Robert J Canter
INTRODUCTION: Variation in treatment and survival outcomes for NSCLC is high among patients with stage III or IV disease, but patients with untreated NSCLC have not been critically analyzed to evaluate for improvable outcomes. We evaluated treatment trends and their association with oncologic outcomes for NSCLC, hypothesizing that there are a substantial number of untreated patients who are similar to patients who undergo treatment. METHODS: Linear regression was used to calculate trends in utilization of treatment...
January 18, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28109288/long-intergenic-non-coding-rna-00152-promotes-lung-adenocarcinoma-proliferation-via-interacting-with-ezh2-and-repressing-il24-expression
#4
Qin-Nan Chen, Xin Chen, Zhen-Yao Chen, Feng-Qi Nie, Chen-Chen Wei, Hong-Wei Ma, Li Wan, Shuai Yan, Sheng-Nan Ren, Zhao-Xia Wang
BACKGROUND: Numerous studies have shown that long non-coding RNAs (lncRNAs) behave as a novel class of transcript during multiple cancer processes, such as cell proliferation, apoptosis, migration, and invasion. LINC00152 is located on chromosome 2p11.2, and has a transcript length of 828 nucleotides. The biological role of LINC00152 in LAD(lung adenocarcinoma) remains unknown. METHODS: Quantitative reverse transcription PCR(qRT-PCR) was used to detect LINC00152 expression in 60 human LAD tissues and paired normal tissues...
January 21, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/28108818/association-between-bone-scan-index-and-activities-of-daily-living-in-patients-with-advanced-non-small-cell-lung-cancer
#5
Ikuno Ito, Kimiteru Ito, Shinichi Takahashi, Mitsuko Horibe, Rui Karita, Chika Nishizaka, Takako Nagai, Kohei Hamada, Hiroyuki Sato, Naoko Shindo
PURPOSE: The aim of this retrospective cross-sectional study was to investigate the association between the bone scan index (BSI) and activities of daily living (ADL) in patients with advanced non-small cell lung cancer (NSCLC). METHODS: Among patients with advanced NSCLC, subjects who underwent bone scintigraphy were recruited from this study. Clinical information about patients, including the Barthel Index of ADL, was extracted from their medical charts. Variables including the age, sex, BSI, presence/absence skeletal-related events (SREs), diagnostic state (initial vs...
January 20, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28108260/triple-negative-metastatic-breast-cancer-is-dependent-on-sphks-s1p-signaling-for-growth-and-survival
#6
Aparna Maiti, Kazuaki Takabe, Nitai C Hait
About 40,000 American women die from metastatic breast cancer each year despite advancements in treatment. Approximately, 15% of breast cancers are triple-negative for estrogen receptor, progesterone receptor, and HER2. Triple-negative cancer is characterized by more aggressive, harder to treat with conventional approaches and having a greater possibility of recurrence. Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid signaling mediator has emerged as a key regulatory molecule in breast cancer progression...
January 17, 2017: Cellular Signalling
https://www.readbyqxmd.com/read/28108151/a-functional-genetic-screen-identifies-the-phosphoinositide-3-kinase-pathway-as-a-determinant-of-resistance-to-fibroblast-growth-factor-receptor-inhibitors-in-fgfr-mutant-urothelial-cell-carcinoma
#7
Liqin Wang, Tonći Šuštić, Rodrigo Leite de Oliveira, Cor Lieftink, Pasi Halonen, Marieke van de Ven, Roderick L Beijersbergen, Michel M van den Heuvel, René Bernards, Michiel S van der Heijden
Activating mutations and translocations of the FGFR3 gene are commonly seen in urothelial cell carcinoma (UCC) of the bladder and urinary tract. Several fibroblast growth factor receptor (FGFR) inhibitors are currently in clinical development and response rates appear promising for advanced UCC. A common problem with targeted therapeutics is intrinsic or acquired resistance of the cancer cells. To find potential drug targets that can act synergistically with FGFR inhibition, we performed a synthetic lethality screen for the FGFR inhibitor AZD4547 using a short hairpin RNA library targeting the human kinome in the UCC cell line RT112 (FGFR3-TACC3 translocation)...
January 17, 2017: European Urology
https://www.readbyqxmd.com/read/28107433/investigation-of-cross-contamination-and-misidentification-of-278-widely-used-tumor-cell-lines
#8
Yaqing Huang, Yuehong Liu, Congyi Zheng, Chao Shen
In recent years, biological research involving human cell lines has been rapidly developing in China. However, some of the cell lines are not authenticated before use. Therefore, misidentified and/or cross-contaminated cell lines are unfortunately commonplace. In this study, we present a comprehensive investigation of cross-contamination and misidentification for a panel of 278 cell lines from 28 institutes in China by using short tandem repeat profiling method. By comparing the DNA profiles with the cell bank databases of ATCC and DSMZ, a total of 46...
2017: PloS One
https://www.readbyqxmd.com/read/28107352/coping-well-with-advanced-cancer-a-serial-qualitative-interview-study-with-patients-and-family-carers
#9
Catherine Walshe, Diane Roberts, Lynda Appleton, Lynn Calman, Paul Large, Mari Lloyd-Williams, Gunn Grande
OBJECTIVES: To understand successful strategies used by people to cope well when living with advanced cancer; to explore how professionals can support effective coping strategies; to understand how to support development of effective coping strategies for patients and family carers. DESIGN: Qualitative serial (4-12 week intervals) interview study with people with advanced cancer and their informal carers followed by focus groups. The iterative design had a novel focus on positive coping strategies...
2017: PloS One
https://www.readbyqxmd.com/read/28107192/incidence-and-risk-of-infections-associated-with-egfr-tkis-in-advanced-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#10
Yingtian Wang, Mingzhen Wang, Qiaoxia Wang, Zhiying Geng, Mingxiang Sun
Currently, the overall incidence and risk of infections with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients remained undetermined. We searched Pubmed for related articles published from 1 January 1990 to 31 November 2015. Eligible studies included prospective randomized controlled trials (RCTs) evaluating therapy with or without EGFR-TKIs in patients with NSCLC. Data on infections were extracted. Pooled incidence, Peto odds ratio (Peto OR), and 95% confidence intervals (CIs) were calculated...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28106046/obp-401-gfp-telomerase-dependent-adenovirus-illuminates-and-kills-high-metastatic-more-effectively-than-low-metastatic-triple-negative-breast-cancer-in-vitro
#11
S Yano, K Takehara, H Kishimoto, H Tazawa, Y Urata, S Kagawa, M Bouvet, T Fujiwara, R M Hoffman
We previously described the development of a highly-invasive, triple-negative breast cancer (TNBC) variant using serial orthotopic implantation of MDA-MB-231 human breast cancer in nude mice. The isolated variant is highly invasive in the mammary gland and metastasized to lymph nodes in 10 of 12 mice compared with 2 of 12 of the parental cell line. OBP-401 is a telomerase-dependent cancer-specific, green fluorescent protein (GFP)-expressing adenovirus. OBP-401 was used to infect parental MDA-MB-231P cells and high-metastatic MDA-MB-231H and MDA-MB-231HLN isolated from a lymph node metastasis and MDA-MB-231HLM isolated from a lung metastasis...
January 20, 2017: Cancer Gene Therapy
https://www.readbyqxmd.com/read/28105777/lung-cancer-and-socio-economic-status-inextricably-linked-to-place-of-residence
#12
E J Denton, D Hart, P A Russell, G Wright, M Conron
BACKGROUND: The association between socioeconomic status (SES) and lung cancer is internationally established but in Australia this relationship remains ill defined. AIMS: To examine the association between SES, place of residence and lung cancer outcomes in a large Australian cohort. METHODS: 2369 consecutive lung cancer patients managed by St Vincent's Hospital lung multidisciplinary meeting between 2001-2014 were included. Postcode data stratified participants by Socio-Economic Indexes for Areas, a validated measure of SES, and by geographical location, an important socioeconomic factor in Australia...
January 20, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28104619/osimertinib-benefit-in-egfr-mutant-nsclc-patients-with-t790m-mutation-detected-by-circulating-tumour-dna
#13
J Remon, C Caramella, C Jovelet, L Lacroix, A Lawson, S Smalley, K Howarth, D Gale, E Green, V Plagnol, N Rosenfeld, D Planchard, M V Bluthgen, A Gazzah, C Pannet, C Nicotra, E Auclin, J C Soria, B Besse
BACKGROUND: Approximately 50% of Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. Osimertinib is the standard of care in this situation. The present study assesses the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour DNA (ctDNA) from blood samples in progressing advanced EGFR-mutant NSCLC patients. MATERIAL AND METHODS: ctDNA T790M mutational status was assessed by Inivata InVision(TM) (eTAm-Seq(TM)) assay in 48 EGFR-mutant advanced NSCLC patients with acquired resistance to EGFR TKIs without a tissue biopsy between April 2015 and April 2016...
January 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28104537/correlation-between-classic-driver-oncogene-mutations-in-egfr-alk-or-ros1-and-22c3-pd-l1-%C3%A2-50-expression-in-lung-adenocarcinoma
#14
Deepa Rangachari, Paul A VanderLaan, Meghan Shea, Xiuning Le, Mark S Huberman, Susumu S Kobayashi, Daniel B Costa
INTRODUCTION: Targeted somatic genomic analysis (EGFR, ALK and ROS1) and PD-L1 tumor proportion score (TPS) by immunohistochemistry (IHC) are used for selection of 1(st)-line therapies in advanced lung cancer; however, the frequency of overlap of these biomarkers in routine clinical practice is poorly reported. METHODS: We retrospectively probed the first 71 lung adenocarcinoma-patient pairs from our institution analyzed for PD-L1 IHC using the clone 22C3 pharmDx kit and evaluated co-occurrence of genomic aberrations along with clinical-pathologic characteristics...
January 16, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28104299/liquid-fiducial-marker-applicability-in-proton-therapy-of-locally-advanced-lung-cancer
#15
Jonas Scherman Rydhög, Rosalind Perrin, Rasmus Irming Jølck, Francis Gagnon-Moisan, Klaus Richter Larsen, Paul Clementsen, Steen Riisgaard de Blanck, Gitte Fredberg Persson, Damien Charles Weber, Tony Lomax, Thomas Lars Andresen, Per Munck Af Rosenschold
BACKGROUND AND PURPOSE: We investigated the clinical applicability of a novel liquid fiducial marker (LFM) for image-guided pencil beam scanned (PBS) proton therapy (PBSPT) of locally advanced lung cancer (LALC). MATERIALS AND METHODS: The relative proton stopping power (RSP) of the LFM was calculated and measured. Dose perturbations of the LFM and three solid markers, in a phantom, were measured. PBSPT treatment planning on computer tomography scans of five patients with LALC with the LFM implanted was performed with 1-3 fields...
January 16, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28103976/-research-progress-of-targeted-therapy-for-anaplastic-lymphoma-kinase-and-other-rare-driver-genes-in-advanced-non-small-cell-lung-cancer
#16
Quan Zhang, Shucai Zhang
Targeted therapy was one of the major treatments in advanced non-small cell lung cancer (NSCLC) with positive driver genes. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers have also undergone deep investigation about the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. This review aimed to summarize the advanced developments of targeted therapy for anaplastic lymphoma kinase (ALK) and other rare driver genes in NSCLC...
January 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28103615/radiation-induced-lung-metastasis-development-is-mt1-mmp-dependent-in-a-triple-negative-breast-cancer-mouse-model
#17
Gina Bouchard, Hélène Therriault, Sameh Geha, Rachel Bujold, Caroline Saucier, Benoit Paquette
BACKGROUND: The prognosis of triple-negative breast cancer (TNBC) is still difficult to establish. Some TNBC benefit from radiotherapy (RT) and are cured, while in other patients metastases appear during the first 3 years after treatment. In this study, an animal model of TNBC was used to determine whether the expression of the cell membrane protease MT1-MMP in cancer cells was associated with radiation-stimulated development of lung metastases. METHODS: Using invasion chambers, irradiated fibroblasts were used as chemoattractants to assess the invasiveness of TNBC D2A1 cell lines showing downregulated expression of MT1-MMP, which were compared with D2A1-wt (wild-type) and D2A1 shMT1-mock (empty vector) cell lines...
January 19, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28103612/a-phase-iii-randomised-controlled-trial-of-erlotinib-vs-gefitinib-in-advanced-non-small-cell-lung-cancer-with-egfr-mutations
#18
J J Yang, Q Zhou, H H Yan, X C Zhang, H J Chen, H Y Tu, Z Wang, C R Xu, J Su, B C Wang, B Y Jiang, X Y Bai, W Z Zhong, X N Yang, Y L Wu
BACKGROUND: A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations in exon 19 or 21. METHODS: Eligible patients were randomised to receive erlotinib (150 mg per day) or gefitinib (250 mg per day) orally until disease progression or unacceptable toxicity. We aimed to determine whether erlotinib is superior to gefitinib in efficacy...
January 19, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28102575/bcl-2-family-in-non-small-cell-lung-cancer-its-prognostic-and-therapeutic-implications
#19
Ping-Li Sun, Hironobu Sasano, Hongwen Gao
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Despite significant advances in its research of tumor biology and therapy, the prognosis for this neoplasm has still remained poor. The great majority of anticancer agents, regardless of their mechanisms of action, exert their lethal actions on cancer cells by inducing apoptosis following drug-induced cellular damage. Many reported studies have evaluated the prognostic and therapeutic implications of apoptosis in lung cancer, but their exact clinical value has remained unclear...
January 19, 2017: Pathology International
https://www.readbyqxmd.com/read/28102437/a-comparison-of-the-effects-of-medical-qigong-and-standard-exercise-therapy-on-symptoms-and-quality-of-life-in-patients-with-advanced-cancer
#20
B L Vanderbyl, M J Mayer, C Nash, A T Tran, T Windholz, T Swanson, G Kasymjanova, R T Jagoe
PURPOSE: Patients with advanced cancer frequently experience anxiety, depression and poor quality of life (QOL), as well as physical symptoms such as fatigue and weakness. Physical exercise has potential to help control these symptoms but the optimal training prescription is still not clear. We performed a study comparing medical Qigong (QG) and standard endurance and strength training (SET) in patients with advanced stage non-small cell lung (NSCLC) and gastrointestinal (GI) cancers...
January 19, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
36943
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"